Table 1.
Baseline characteristics of LAGC patients with neoadjuvant therapy.
| All | Chemo | Io+Chemo | P value | |
|---|---|---|---|---|
| Age (yr) | 0.251 | |||
| Median (range) | 59.71 (25~85) | 60.06 (25~79) | 59.35 (33~85) | |
| <55 | 81 (63.3) | 38 (58.5) | 43 (68.3) | |
| ≥55 | 47 (36.7) | 27 (41.5) | 20 (31.7) | |
| Gender | 0.152 | |||
| Male | 90 (70.3) | 42 (64.6) | 48 (76.2) | |
| Female | 38 (29.7) | 23 (35.4) | 15 (23.8) | |
| cTNM, before NAT | 0.288 | |||
| II | 43 (33.6) | 19 (29.2) | 24 (38.1) | |
| III | 85 (66.4) | 46 (70.8) | 39 (61.9) | |
| ypT | 0.002 | |||
| 0-2 | 44 (34.4) | 14 (21.5) | 30 (47.6) | |
| 3-4 | 84 (65.6) | 51 (78.5) | 33 (52.4) | |
| ypN | 0.010 | |||
| 0-1 | 77 (60.2) | 32 (49.2) | 45 (71.4) | |
| 2-3 | 51 (39.8) | 33 (50.8) | 18 (28.6) | |
| ypTNM | 0.005 | |||
| 1 | 40 (31.3) | 13 (20) | 27 (42.9) | |
| 2-3 | 88(68.8) | 52(80) | 36(57.1) | |
| Histological type | 0.058 | |||
| Adenocarcinoma | 94(73.4) | 43(66.2) | 51(81.0) | |
| Poorly cohesive carcinoma | 34(26.6) | 22(33.8) | 12(19.0) | |
| Grade of differentiation | 0.072 | |||
| Well and moderately differentiated | 45(35.2) | 18(27.7) | 27(42.9) | |
| Poorly differentiated | 83(64.8) | 47(72.3) | 36(57.1) | |
| Lauren classification | 0.052 | |||
| Intestinal | 52(40.6) | 21(32.3) | 31(49.2) | |
| Diffuse or mixed | 76(59.4) | 44(67.7) | 32(50.8) | |
| Nervous invasion | 0.606 | |||
| No | 58(45.3) | 28(43.1) | 30(47.6) | |
| Yes | 70(54.7) | 37(56.9) | 33(52.4) | |
| Vascular or lymphatic invasion | 0.379 | |||
| No | 66(51.6) | 36(55.4) | 30(47.6) | |
| Yes | 62(48.4) | 29(44.6) | 33(52.4) | |
| PD-L1 | 0.613 | |||
| CPS<5 | 76(59.4) | 40(61.5) | 36(57.1) | |
| CPS≥5 | 52(40.6) | 25(38.5) | 27(42.9) | |
| MMR | 0.848 | |||
| pMMR | 111(86.7) | 56(86.2) | 55(87.3) | |
| dMMR | 17(13.3) | 9(13.8) | 8(12.7) |
LAGC, local advantage gastric cancer. Bold values were statistically significant (P < 0.05).